RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1005 participants.

Also called NCT02303795

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,005 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02303795
Other papers using this trial's data
  • Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve The New England journal of medicine, 2020-11-26 DOI, PubMed 33196155

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02303795. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2020-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
Condition
Valvular Heart Disease
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Warfarin
Lead sponsor
Hospital do Coracao (class: other)

Record details

Record id
cardio:ct-nct02303795
Content hash
a33cc0708b2581e8280eaeea571f068e8300cfb720c55525834631f0568d8595